Imricor Medical Systems (ASX:IMR) signed a license agreement with Swiss software company Adis SA to commercialize artificial intelligence (AI) modules integrated within its NorthStar 3D mapping system, according to a Thursday filing with the Australian bourse.
The company will provide NorthStar AI modules as software license options, sharing upfront and ongoing revenue with ADIS under the deal, the filing said.
NorthStar and AI modules are undergoing regulatory processes for commercial sale, with plans for launch in Europe, the US, and the Middle East in 2025.
The first module the companies are targeting is one for providing automatic heart segmentation capabilities to NorthStar, which is expected to save time during interventional cardiovascular magnetic resonance procedures by creating 3D anatomical shells of heart chambers from standard MRI images, according to the filing.
Financial terms of the deal were not disclosed.
Imricor Medical Systems shares rose almost 15% in morning trade Thursday and earlier hit their highest since November 2021.
Price (AUD): $1.23, Change: $+0.16, Percent Change: +14.95%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.